Cargando…
Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study
AIMS: This multicenter, open‐label, randomized study (Registration No. ChiCTR‐OCH‐14004528) aimed to compare the efficacy and effects of oxcarbazepine (OXC) with levetiracetam (LEV) as monotherapies on patient quality of life and mental health for patients with newly diagnosed focal epilepsy from Ch...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160445/ https://www.ncbi.nlm.nih.gov/pubmed/35429132 http://dx.doi.org/10.1111/cns.13840 |
_version_ | 1784719269563465728 |
---|---|
author | Zhu, Haoyue Deng, Xuejun Feng, Li Lian, Yajun Han, Xiong Guo, Zhenli Gou, Yulan Du, Yuanmin Xie, Longshan Yao, Dongai Liu, Yonghong Wu, Qiang Lan, Song Liu, Kaisheng Zhan, Peiyan Wang, Xiahong Dang, Jingxia Hou, Yunqi Chen, Keqiang Zhu, Yulan Shi, Yuliang Yu, Yunli Xiao, Bo Zhu, Suiqiang Meng, Hongmei |
author_facet | Zhu, Haoyue Deng, Xuejun Feng, Li Lian, Yajun Han, Xiong Guo, Zhenli Gou, Yulan Du, Yuanmin Xie, Longshan Yao, Dongai Liu, Yonghong Wu, Qiang Lan, Song Liu, Kaisheng Zhan, Peiyan Wang, Xiahong Dang, Jingxia Hou, Yunqi Chen, Keqiang Zhu, Yulan Shi, Yuliang Yu, Yunli Xiao, Bo Zhu, Suiqiang Meng, Hongmei |
author_sort | Zhu, Haoyue |
collection | PubMed |
description | AIMS: This multicenter, open‐label, randomized study (Registration No. ChiCTR‐OCH‐14004528) aimed to compare the efficacy and effects of oxcarbazepine (OXC) with levetiracetam (LEV) as monotherapies on patient quality of life and mental health for patients with newly diagnosed focal epilepsy from China. METHODS: Patients with newly diagnosed focal epilepsy who had experienced 2 or more unprovoked seizures at greater than a 24‐h interval during the previous year were recruited. Participants were randomly assigned to the OXC group or LEV group. Efficacy, safety, quality of life, and mental health were evaluated over 12‐week and 24‐week periods. RESULTS: In total, we recruited 271 newly diagnosed patients from 23 centers. Forty‐four patients were excluded before treatment for reasons. The rate of seizure freedom of OXC was significantly superior to that of LEV at 12 weeks and 24 weeks (p < 0.05). The quality of life (except for the seizure worry subsection) and anxiety scale scores also showed significant differences from before to after treatment in the OXC and LEV groups. CONCLUSIONS: OXC monotherapy may be more effective than LEV monotherapy in patients with newly diagnosed focal epilepsy. Both OXC and LEV could improve the quality of life and anxiety state in adult patients with focal epilepsy. |
format | Online Article Text |
id | pubmed-9160445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91604452022-06-04 Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study Zhu, Haoyue Deng, Xuejun Feng, Li Lian, Yajun Han, Xiong Guo, Zhenli Gou, Yulan Du, Yuanmin Xie, Longshan Yao, Dongai Liu, Yonghong Wu, Qiang Lan, Song Liu, Kaisheng Zhan, Peiyan Wang, Xiahong Dang, Jingxia Hou, Yunqi Chen, Keqiang Zhu, Yulan Shi, Yuliang Yu, Yunli Xiao, Bo Zhu, Suiqiang Meng, Hongmei CNS Neurosci Ther Original Articles AIMS: This multicenter, open‐label, randomized study (Registration No. ChiCTR‐OCH‐14004528) aimed to compare the efficacy and effects of oxcarbazepine (OXC) with levetiracetam (LEV) as monotherapies on patient quality of life and mental health for patients with newly diagnosed focal epilepsy from China. METHODS: Patients with newly diagnosed focal epilepsy who had experienced 2 or more unprovoked seizures at greater than a 24‐h interval during the previous year were recruited. Participants were randomly assigned to the OXC group or LEV group. Efficacy, safety, quality of life, and mental health were evaluated over 12‐week and 24‐week periods. RESULTS: In total, we recruited 271 newly diagnosed patients from 23 centers. Forty‐four patients were excluded before treatment for reasons. The rate of seizure freedom of OXC was significantly superior to that of LEV at 12 weeks and 24 weeks (p < 0.05). The quality of life (except for the seizure worry subsection) and anxiety scale scores also showed significant differences from before to after treatment in the OXC and LEV groups. CONCLUSIONS: OXC monotherapy may be more effective than LEV monotherapy in patients with newly diagnosed focal epilepsy. Both OXC and LEV could improve the quality of life and anxiety state in adult patients with focal epilepsy. John Wiley and Sons Inc. 2022-04-15 /pmc/articles/PMC9160445/ /pubmed/35429132 http://dx.doi.org/10.1111/cns.13840 Text en © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Zhu, Haoyue Deng, Xuejun Feng, Li Lian, Yajun Han, Xiong Guo, Zhenli Gou, Yulan Du, Yuanmin Xie, Longshan Yao, Dongai Liu, Yonghong Wu, Qiang Lan, Song Liu, Kaisheng Zhan, Peiyan Wang, Xiahong Dang, Jingxia Hou, Yunqi Chen, Keqiang Zhu, Yulan Shi, Yuliang Yu, Yunli Xiao, Bo Zhu, Suiqiang Meng, Hongmei Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study |
title | Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study |
title_full | Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study |
title_fullStr | Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study |
title_full_unstemmed | Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study |
title_short | Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open‐label, randomized study |
title_sort | efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in china: a multicenter, open‐label, randomized study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160445/ https://www.ncbi.nlm.nih.gov/pubmed/35429132 http://dx.doi.org/10.1111/cns.13840 |
work_keys_str_mv | AT zhuhaoyue efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT dengxuejun efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT fengli efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT lianyajun efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT hanxiong efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT guozhenli efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT gouyulan efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT duyuanmin efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT xielongshan efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT yaodongai efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT liuyonghong efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT wuqiang efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT lansong efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT liukaisheng efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT zhanpeiyan efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT wangxiahong efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT dangjingxia efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT houyunqi efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT chenkeqiang efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT zhuyulan efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT shiyuliang efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT yuyunli efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT xiaobo efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT zhusuiqiang efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy AT menghongmei efficacycomparisonofoxcarbazepineandlevetiracetammonotherapyamongpatientswithnewlydiagnosedfocalepilepsyinchinaamulticenteropenlabelrandomizedstudy |